ArabicChineseEnglishFrenchRussianSpanish
WHO home
All WHO This site only
  Immunization, Vaccines and Biologicals
  WHO > WHO sites > Immunization, Vaccines and Biologicals > IVB Topics
printable version

Haemophilus influenzae type b (Hib): Previous page | 1,2,3,4

Key Points and Vaccine summary

  Table of contents for Hib

Key Points

  • Hib’s victims are mainly children younger than five years old.
  • Hib bacteria are commonly present in the nose and throat. The bacteria are transmitted from person to person in droplets through sneezing, coughing.
  • Infected children may carry Hib bacteria without showing any signs or symptoms of the disease, which may kill up to 5% to 10% of infected children. Others suffer permanent disabilities.
  • Hib disease can cause pneumonia and meningitis.
  • Hib disease can be treated with antibiotics.
  • Hib disease can be prevented with vaccine given early in infancy.

Vaccine summary

  • Type of vaccine: Conjugate
  • Number of doses: two or three doses (depending on manufacturer)
  • Schedule: 6, 10, 14 weeks of age for three doses schedule (depending on manufacturer)
  • Booster: None
  • Contraindications: Hypersensitivity to previous dose
  • Adverse reactions: Mild local reaction
  • Special precautions: None
  • Dosage: 0.5ml
  • Injection site: Outer mid-thigh for infants. Outer upper arm for older children
  • Injection type: Intramuscular
  • Storage: Store between 2°C–8°C

Haemophilus influenzae type b (Hib): 1,2,3,4

[an error occurred while processing this directive]